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Following an acute coronary syndrome (ACS), patients remain at risk for new ischaemic events, regardless of the type of presentation or the initial management. Although a substantial proportion of the recurrent events occur in the first months, there is a continuing accruement of new ischaemic events afterwards. 1 As a consequence, guidelines recommend a P2Y 12 inhibitor to be added to low-dose aspirin for the first year following an ACS, whether or not a percutaneous coronary intervention (PCI) is performed, and to continue low-dose aspirin alone indefinitely. The recommended duration of 1 year of dual antiplatelet therapy (DAPT) after an ACS is arbitrarily based on the treatment duration in the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) trial, the first outcome trial on DAPT in ACS. 2 Because DAPT puts ACS patients at an increased risk of bleeding complications, P2Y 12 inhibitors are often deliberately discontinued before 1 year because of the occurrence of bleeding or a perceived or real high bleeding risk. On the other hand, registries have shown, surprisingly, that in a significant proportion of ACS patients DAPT is continued beyond 1 year because neither ischaemic nor bleeding events had occurred (the 'never change a winning team' approach). 3, 4 The superiority of ticagrelor and prasugrel over clopidogrel in the first year following an ACS has been clearly established in two pivotal large international trials. 5, 6 Landmark analyses of these trial data show a greater reduction in recurrent ischaemic events with these new agents throughout the year following the event, thus not only during the acute phase but also afterwards. 7, 8 Ticagrelor and prasugrel (the latter with some restrictions) are hence unequivocally recommended on top of low-dose aspirin for 1 year after an ACS. 9, 10 Clopidogrel only remains a recommended option for ACS patients without access to either ticagrelor or prasugrel. Still, ever since these trials, cardiologists have wondered whether tiered, step-wise approaches could be as effective and perhaps safer than the guidelines recommendations. One option among many, for instance, is switching to clopidogrel at discharge or a few weeks later instead of continuing prasugrel or ticagrelor. Issues with reimbursement or availability, or with a perceived bleeding risk are assumed to justify a switch to the less potent and cheaper P2Y 12 inhibitor clopidogrel. In this issue of the journal, Cuisset and colleagues report the results of the Timing Of Platelet Inhibition after acute Coronary syndrome (TOPIC) study, the first randomized clinical trial investigating a switch from prasugrel or ticagrelor to clopidogrel vs. continuing either drug after a PCI for ACS. 11 A total of 646 patients with an STsegment elevation myocardial infarction (STEMI), non-STEMI, or unstable angina who did not experience an ischaemic or bleeding event in the first 30 days after the event were then randomized to either strategy. The TOPIC investigators need to be commended for conducting this first randomized clinical trial investigating a 'downgrading' of the DAPT regimen in stabilized ACS patients. The randomization of 646 patients in a single centre and successfully following these patients up to 1 year is a testimony of their hard work. While the results from TOPIC are certainly intriguing, they obviously need be interpreted in view of the limitations of this singlecentre trial. The open-label nature of the trial, the telephonebased follow-up, the internal event adjudication, as well as an envelope system of randomization warrant a judicious interpretation. Importantly, the number of patients lost to follow-up plus the patients crossing over to the other treatment strategy arm exceeds the total number of many of the individual endpoints which also prohibits making definite conclusions.
Other 'idiosyncrasies' of TOPIC also deserve further comments. An unknown proportion of patients in this trial did not have elevated cardiac markers of necrosis at the time of their ACS but, together with non-STEMI patients, they appear to constitute the majority of patients included here (60%). In this era of high-sensitivity troponin, one can only wonder to what extent these unstable angina patients differ from stable PCI patients who are known to do very well on aspirin and clopidogrel after PCI. Also, while events with ticagrelor vs. prasugrel were not reported separately, 10 mg of prasugrel was used, without a reduced dose in the elderly (ESC guidelines do recommend using 5 mg in this population). It remains unclear how many elderly patients were on the 10 mg dose, and how many of these patients contributed to the total number of bleeding complications. Finally, the most difficult to interpret quirk of TOPIC is the occurrence of events in the first month before the randomization at day 30, despite significant ischaemic or bleeding events during this first month being exclusion criteria. Even when most events occur between day 30 and 1 year, judging from the event curves, prerandomization events appear to disfavour the unchanged DAPT arm during the first month.
Taken together, the results of TOPIC obviously do not invalidate the superiority of ticagrelor or prasugrel over clopidogrel as observed in the much larger, double-blind, multicentre trials, and as a consequence cannot influence clinical practice and affect future guidelines. They may, however, add fuel to the debate on individualizing and optimizing post-ACS treatment. There still remain many options for long-term anti-thrombotic treatment after an ACS. Some of them have not found their way into clinical practice, such as adding a low dose of rivaroxaban to aspirin and clopidogrel in spite of a mortality reduction shown in the Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 51 (ATLAS ACS 2-TIMI 51) trial, although this may change when the results of the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial will become available. Other options are worth exploring in new outcome trials, e.g. a lower dose of ticagrelor or prasugrel after a few days or 1 month, switching to clopidogrel as done in TOPIC but in specific subgroups based for instance on age or bleeding risk or on platelet and genetic testing results, or discontinuing aspirin altogether and keeping the patient on ticagrelor or prasugrel alone ( Figure 1) . From this viewpoint, TOPIC is not a return to square one in post-ACS management, but hopefully the first square in a new board game of tailored antithrombotic strategies in the post-ACS setting. 
